Core Insights - The "High Income DIY Portfolios" service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees [1] - The service offers a total of 10 model portfolios, including various strategies for income generation and risk management, with a focus on sustainable yields [2] Group 1: Portfolio Strategies - The service includes seven portfolios: three buy-and-hold, three rotational portfolios, and a conservative NPP strategy portfolio designed for low drawdowns and high growth [1] - The investment approach emphasizes dividend-growing stocks and aims for a 30% reduction in drawdowns while targeting a 6% current income [2] Group 2: Additional Features - The service provides buy and sell alerts, live chat, and strategies for portfolio management and asset allocation to help investors achieve stable, long-term passive income [2]

CVS Health Corporation (NYSE:CVS) is included among the 20 Best Performing Dividend Stocks in 2025. JPMorgan Names CVS a Top Pick as Turnaround Gains Traction The stock dropped 43% in 2024, then swung the other way with an 80.5% gain this year. Even after that run, Wall Street still sees room to move. The average analyst price target points to another 19% upside.Earlier in December, JPMorgan named CVS Health Corporation (NYSE:CVS) as a top pick in health care services. “We remain positive on CVS post-Inv ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.Below are the ratings of the most accurate analysts for three high-yield ...

CVS Health Corporation (NYSE:CVS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. CVS Gets Higher Target as Bernstein Cites Management Confidence On December 12, Bernstein raised the firm’s price target on CVS Health Corporation (NYSE:CVS) to $87 from $86 and kept a Market Perform rating after what it described as a very positive Investor Day. The firm pointed to stronger confidence in the quality and depth of the management team, along with renewed conviction in the company’s market ...

Core Insights - CVS Health's stock closed at $79.12, reflecting a +1.38% increase from the previous day, outperforming the S&P 500's gain of 0.32% [1] - Over the past month, CVS shares have decreased by 0.55%, underperforming the Medical sector's increase of 1.67% and the S&P 500's increase of 4.7% [1] Financial Performance - CVS Health is expected to report earnings of $0.99 per share, indicating a year-over-year decline of 16.81%, with projected quarterly revenue of $103.03 billion, up 5.44% from the previous year [2] - For the full year, analysts anticipate earnings of $6.65 per share and revenue of $399.4 billion, representing increases of +22.69% and +7.13% respectively from last year [3] Analyst Estimates - Recent modifications to analyst estimates for CVS Health reflect evolving short-term business trends, with positive changes indicating a favorable outlook on business health and profitability [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks CVS Health at 3 (Hold), with a 0.48% increase in the consensus EPS estimate over the last 30 days [6] Valuation Metrics - CVS Health is trading at a Forward P/E ratio of 11.73, which is below the industry average Forward P/E of 15.51 [7] - The company has a PEG ratio of 0.77, compared to the Medical Services industry's average PEG ratio of 1.71, indicating a more favorable valuation relative to expected earnings growth [7] Industry Context - The Medical Services industry, which includes CVS Health, has a Zacks Industry Rank of 153, placing it in the bottom 39% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the competitive landscape within the industry [8]

Inflation is still eating away at people's budgets, as only the pace has slowed, that too at a snail's pace. ...

Key Points VCLT charges a lower expense ratio and offers a higher yield than LQD LQD has outperformed VCLT over the past year and experienced a smaller five-year drawdown VCLT holds far fewer bonds, with sector tilts and an ESG screen, while LQD is much broader These 10 stocks could mint the next wave of millionaires › The iShares iBoxx Investment Grade Corporate Bond ETF (LQD) and the Vanguard Long-Term Corporate Bond ETF (VCLT) differ most in cost, yield, sector exposure, and risk profile, wit ...

North America Equity Research December 2025 Healthcare Services 2026 Outlook: It's Different This Time: Potential for Margin Improvement and Policy Clarity Create a Positive Backdrop Conference Call Details Tuesday, December 17 @ 10:00am ET / 15:00 UK Dial-in Info: Please contact us or your JPM salesperson for details Replay Info: Available approximately 2-3 hours after the call ends Healthcare Services Lisa C. Gill AC (212) 622-6466 lisa.c.gill@jpmorgan.com Bloomberg JPMA GILL J.P. Morgan Securities LLC Ma ...

Core Insights - President Trump announced a set of drug-pricing agreements with nine major pharmaceutical companies, aiming to align U.S. medicine costs with those in Europe [1][2] - The initiative includes a new direct-to-consumer portal, TrumpRx.gov, allowing patients to purchase certain medicines directly from manufacturers [2][4] Group 1: Agreements and Participants - The agreements involve 14 out of 17 drugmakers that Trump previously urged to lower prices, including Amgen, GSK, and Merck [2][3] - Drug companies are motivated to negotiate to avoid potential regulatory measures that could impact their profits [3] Group 2: TrumpRx.gov Functionality - TrumpRx.gov will serve as a central directory for patients to access selected medicines directly from manufacturers' websites [4] - The portal is expected to be fully operational by January, following a promotional launch [4] Group 3: Pricing Details - Highlighted medicines include Amgen's Repatha at $239/month, GSK's Advair Diskus at $89/month, and Merck's Januvia at $100/month [6] - Gilead's Epclusa will be priced at $2,492/month, despite lower costs for insured patients [6] Group 4: Impact on Medicaid and Medicare - Companies committed to launching new medicines in the U.S. at prices comparable to those in other wealthy countries [8] - Medicaid programs are legally entitled to the lowest drug prices, with Bristol Myers Squibb offering Eliquis free to Medicaid [9] Group 5: Industry Response and Future Outlook - Health policy experts express skepticism about the agreements' impact on overall drug prices for most Americans [10] - The agreements do not impose mandatory price controls and leave many brand-name drug costs unchanged [15] - Ongoing discussions with additional manufacturers like AbbVie and Johnson & Johnson may lead to further agreements [14]

在特朗普发表上述言论后，包括哈门那（Humana，HUM）、联合健康（UnitedHealthcare，UNH）、信 诺（Cigna，CI）、CVS健康（CVS Health，CVS）和Elevance Health（ELV）在内的股票，要么回吐涨 幅，要么进一步下跌。特朗普此番言论是在一场宣布与九家制药公司达成定价协议的新闻活动结束时作 出的。 "我将召集那些已经变得非常富有的大型保险公司开会，"特朗普表示，并指出他将游说它们降低价格。 "我想，也许只要谈一次，他们就愿意把价格削减50%、60%甚至70%。他们已经赚得盆满钵满。" 在特朗普发表上述言论后，包括哈门那（Humana，HUM）、联合健康（UnitedHealthcare，UNH）、信 诺（Cigna，CI）、CVS健康（CVS Health，CVS）和Elevance Health（ELV）在内的股票，要么回吐涨 幅，要么进一步下跌。特朗普此番言论是在一场宣布与九家制药公司达成定价协议的新闻活动结束时作 出的。 "我将召集那些已经变得非常富有的大型保险公司开会，"特朗普表示，并指出他将游说它们降低价格。 "我想，也许只要谈一次，他们就愿意把价格 ...